antibacterial agent

Antibacterialagent (compound 8b) is a potent antimicrobial compound. It exhibits significant antibacterial activity against E. coli and S. aureus, with IC50 values of 64 µg/mL and 32 µg/mL, respectively.

Anti bacterial agent 236 (Compound 4l), an orally effective inhibitor of DNA gyrase and topoisomerase IV (with IC50 values of 3.2 and 300 nM in Staphylococcus aureus, respectively), exhibits broad-spectrum antibacterial activity. It also demonstrates favorable pharmacokinetic properties in mice.

Compound thy2I, also known as Anti bacterial agent 235, exhibits antibacterial activity with a minimum inhibitory concentration (MIC) ranging from 0.5 μg/mL to 8 μg/mL. This compound effectively targets and kills both Gram-positive and Gram-negative bacteria via a membrane-targeting mechanism and possesses a low resistance frequency.

Antibacterial agent 243 is a potent antimicrobial compound with EC50 values of 0.64 mg/L for Valsa mali, 26 mg/L for allicin, and 0.33 mg/L for tebuconazole. It induces hyphal contraction and collapse, triggers the accumulation of reactive oxygen species within cells, modulates antioxidant enzyme activity, initiates lipid peroxidation, and ultimately causes irreversible oxidative damage to Valsa mali cells.

Antibacterial agent 242, a potent inhibitor of 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR), demonstrates an IC50 of 5.46 μM against Toxoplasma gondii. It effectively inhibits the enzymatic activity of TgDXR in vitro as well as the proliferation of T. gondii.

Antibacterial agent 246 (compound A33) demonstrates a minimum inhibitory concentration (MIC) ranging from 0.5 to 4 μg/mL against 23 species of Gram-positive bacteria. When used in combination with Polymyxin E, it inhibits the growth of various Gram-negative bacteria, showing a partial inhibitory concentration index of 0.066.

Antibacterialagent 247 (compound 30b) is a bacterium (bacterial) antagonist that significantly inhibits the formation of biofilms by Pseudomonas aeruginosa (IC50=5.8 μM) and various virulence phenotypes. It also enhances the antibacterial activity of combined treatments with tobramycin and polymyxin B.

Antibacterialagent 255 (compound (±)-1) is a potent antibacterial agent, acting as an effective and selective inhibitor of 4-diphosphocytidyl-2-C-methyl-D-erythritol (IspE). It exhibits IC50 values of 13.0, 8.0, and 20 µM against EclspE, KplspE, and AblspE, respectively.

Antibacterialagent 262 (compound A23) is a potent antibacterial agent that inhibits the activity of Xanthomonas oryzae pv oryzae. It also disrupts the integrity of bacterial cell membranes by preventing the formation of biofilms of Xanthomonas oryzae pv oryzae.

Antibacterialagent 119 (Compound 21 g) is a potential antibacterial agent effective against methicillin-resistant Staphylococcus aureus, with a minimum inhibitory concentration (MIC) of less than 1 μg/mL against tested strains. It induces reactive oxygen species (ROS) generation and disrupts bacterial cell membranes, causing their rupture. Antibacterialagent 119 exhibits strong antimicrobial activity, low cytotoxicity, rapid bactericidal action, and favorable in vivo antibacterial efficacy.

Antibacterialagent 263 (compound 5a) is a potent antibacterial agent, exhibiting activity against Streptococcus mutans and Staphylococcus aureus.

Antibacterialagent 272 (Compound Z22) is a potential antibacterial agent that targets the DNA and DNA-topoisomerase II (DNA-Topo II) complex. It exhibits strong antibacterial activity, with a minimum inhibitory concentration (MIC) of 1 μg/mL against Staphylococcus aureus 25923 and 29213, 2 μg/mL against Staphylococcus epidermidis 12228, 2-4 μg/mL against Enterococcus faecalis, and 4 μg/mL against Pseudomonas aeruginosa 9027 and 27853. Antibacterialagent 272 binds by intercalating between DNA base pairs, disrupting the normal function of bacterial DNA, and is suitable for research into bacterial infectious diseases.

Antibacterialagent 274 (Compound 18b) is an antibacterial agent that targets bacterial cell membranes, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL against Acinetobacter baumannii ATCC 17978. It functions by disrupting membrane integrity, causing intracellular accumulation of ROS, which leads to DNA and protein leakage, thereby exerting its antibacterial effects. Antibacterialagent 274 is applicable in research on infections caused by Gram-negative bacteria.

Antibacterialagent 279 (compound A12) is an effective antibacterial agent. It inhibits the SOS response of Pseudomonas aeruginosa.

Antibacterialagent 185 (compound IP-01) is a potent antibacterial agent. It inhibits the polymerization and bundling of filamentous temperature-sensitive mutant Z (FtsZ) by enhancing GTP hydrolysis. Antibacterialagent 185 is effective against Streptococcus pneumoniae and displays a narrow spectrum of activity.

Antibacterialagent 178 (compound A10) is an effective antimicrobial agent. It demonstrates antibacterial activity with EC50 values of 5.32 mg/L against Xanthomonas oryzae pv. oryzae and 7.58 mg/L against Xanthomonas oryzae pv. oryzicola. Antibacterialagent 178 targets the translation regulator factor (CsrA) and virulence regulator factor (Xoc3530).

Antibacterialagent 182 (compound 8c) is an antibacterial agent that exhibits activity against various Gram-positive bacteria, particularly displaying efficacy against vancomycin-resistant Enterococcus faecium (MIC ≤0.125 μg/mL). At sub-MIC levels, Antibacterialagent 182 can inhibit biofilm formation by Staphylococcus aureus and Pseudomonas aeruginosa.

Antibacterialagent 179 (Compound 23) is a potent antibacterial agent that effectively kills both Gram-negative and Gram-positive bacteria. In murine models of corneal infections caused by Staphylococcus aureus or Pseudomonas aeruginosa, Antibacterialagent 179 demonstrates significant in vivo antibacterial activity.

Antibacterialagent 186 (compound 25) is a potent antibacterial agent that demonstrates anti-biofilm formation properties against clinical strains of Staphylococcus epidermidis and has the capability to eradicate existing biofilms. It also holds potential for studying multidrug-resistant strains of Staphylococcus epidermidis.

Antibacterialagent 190 (compound 16) is an antibacterial agent that demonstrates antimicrobial activity and reduces bacterial load in both blood and peritoneum.

Antibacterial agent 193 (Compound 2n) is a spiramycin A monobenzyl derivative exhibiting antibacterial activity against the plant pathogen Rhizoctonia solani, with an IC50 value of 5.25 μg/mL.

Antibacterialagent 189 (compound 3a) is a potent antibacterial agent with high binding affinity to the target proteins OMPA/exo-1,3-β-glucanase. It demonstrates effective antibacterial activity against Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, Bacillus subtilis, Candida albicans, and Aspergillus flavus. Additionally, Antibacterialagent 189 exhibits strong binding affinity to the target proteins SMO and SUFU/GLI-1.

Antibacterialagent 202 (Compound 45c) is a low-cytotoxicity antibacterial agent (Bacterialinhibitor) that exhibits good activity against Gram-negative bacteria, including Escherichia coli, Klebsiella pneumoniae, and particularly Pseudomonas aeruginosa, with a minimum inhibitory concentration (MIC) of 7.8-31.25 μM. It exerts its antibacterial effect by disrupting cell membrane integrity and is useful for research on bacterial infections.

Antibacterial agent 212 (Compound 162) is an orally active antimicrobial with favorable pharmacokinetic properties, demonstrating a minimum inhibitory concentration (MIC) of 4 μg/mL against Pseudomonas aeruginosa T-2022-D2-048.